<DOC>
	<DOCNO>NCT00750256</DOCNO>
	<brief_summary>A first-time human study investigate safety , tolerability , pharmacokinetics pharmacodynamics GSK1278863A healthy subject</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics Pharmacodynamics GSK1278863A Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Healthy , nonsmoking ( within 40 day screen ) , adult male females 18 55 year age , inclusive Female subject eligible participation study : Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) ; Male subject agree use contraception method Body weight &gt; = 50 kg ; BMI : 1931 kg/m2 , inclusive Subject QTc &lt; 450 msec &lt; 480 msec associate bundle branch block Subject willing able provide write informed consent MCV value outside reference range screen Hemoglobin value screening : male subject postmenopausal female &gt; 15.5 g/dL ; female subject &gt; 14.5 g/dL TIBC , serum iron serum ferritin value outside reference range screen Calculated creatinine clearance &lt; 60 ml/min Clinically significant abnormal CPK determine investigator medical monitor AST , ALT direct bilirubin great upper limit reference range screen Subjects unwilling inability follow procedure lifestyle and/or dietary restriction outline protocol Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication , unless opinion Investigator GSK Medical Monitor interfere study procedure compromise subject safety Subject currently exposures four new chemical entity within 12 month prior first dose day Use prescription nonprescription drug , vitamin , herbal dietary supplement , within 7 day prior first dose study medication Subject history sensitivity study medication , component thereof history drug allergy Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subject history GI ulceration gastrointestinal bleeding Subject history peptic ulcer disease Subject history malignancy tumor ; nonmelanoma skin cancer definitely remove allow Treatment investigational drug within 30 day precede first dose study medication Subjects history drug abuse History regular alcohol consumption exceed 7 drinks/week female 14 drinks/week men ( 1 drink = 5 ounce wine 12 ounce beer 1.5 ounce hard liquor ) within 6 month screen Positive urine drug screen ( UDS ) screen Positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result positive HIV result within 3 month screen Donation blood excess 500 mL within 56 day prior first dose study medication Subject history regular use tobacco nicotine containing product History sensitivity heparin , heparininduced thrombocytopenia sensitivity study medication component thereof</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Safety</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>tolerability</keyword>
</DOC>